We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+17.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.6B
AUM Growth
+$255M
Cap. Flow
-$1.97M
Cap. Flow %
-0.08%
Top 10 Hldgs %
27.03%
Holding
158
New
8
Increased
60
Reduced
24
Closed
11

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$19.4M
2
UNH icon
UnitedHealth
UNH
+$19.2M
3
WST icon
West Pharmaceutical
WST
+$14.7M
4
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$12.2M
5
ARGX icon
argenx
ARGX
+$11.5M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.1M
2
AET
Aetna Inc
AET
+$40.4M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$23.5M
4
PRAH
PRA Health Sciences, Inc.
PRAH
+$9.19M
5
ZTS icon
Zoetis
ZTS
+$8.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
76
BioMarin Pharmaceuticals
BMRN
$12.4B
$11.8M 0.45%
125,000
– –
CLVS
77
DELISTED
Clovis Oncology, Inc.
CLVS
$11.6M 0.45%
255,000
+23,500
+10% +$1.14M
RIGL icon
78
Rigel Pharmaceuticals
RIGL
$750M
$11.2M 0.43%
395,000
+137,500
+53% +$4.89M
TVTX icon
79
Travere Therapeutics
TVTX
$5.78B
$10.9M 0.42%
400,000
– –
ARGX icon
80
argenx
ARGX
$54.1B
$10.7M 0.41%
+128,750
New +$11.5M
ANAB icon
81
AnaptysBio
ANAB
$1.68B
$10.7M 0.41%
150,000
+15,000
+11% +$1.26M
CLSD
82
DELISTED
Clearside Biomedical
CLSD
$10.4M 0.4%
65,000
– –
NVTA
83
DELISTED
Invitae Corporation
NVTA
$10.3M 0.4%
1,400,000
– –
A icon
84
Agilent Technologies
A
$41.2B
$10.1M 0.39%
163,700
+72,200
+79% +$4.71M
ZGNX
85
DELISTED
Zogenix, Inc.
ZGNX
$9.99M 0.38%
226,000
+500
+0.2% +$20.6K
CHRS icon
86
Coherus Oncology
CHRS
$196M
$9.66M 0.37%
690,000
-5,000
-0.7% -$71.6K
QTTB icon
87
Q32 Bio
QTTB
$464M
$9.59M 0.37%
26,111
-5,833
-18% -$2.09M
FPRX
88
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$9.38M 0.36%
593,000
+7,500
+1% +$131K
ARDX icon
89
Ardelyx
ARDX
$997M
$9.35M 0.36%
2,525,557
+250,000
+11% +$1.16M
ECYT
90
DELISTED
Endocyte, Inc. Common Stock
ECYT
$9.31M 0.36%
675,000
– –
MNTA
91
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$9.25M 0.36%
452,500
+107,500
+31% +$2.31M
SRGA
92
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$8.97M 0.35%
65,000
– –
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
$8.9M 0.34%
750,000
-125,000
-14% -$1.56M
ODT
94
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$8.78M 0.34%
397,750
+14,250
+4% +$332K
CO
95
DELISTED
Global Cord Blood Corporation
CO
$8.35M 0.32%
880,000
– –
APTX
96
DELISTED
Aptinyx Inc. Common Stock
APTX
$8.22M 0.32%
+340,000
New +$7.28M
CBAY
97
DELISTED
Cymabay Therapeutics
CBAY
$7.78M 0.3%
580,000
+90,000
+18% +$1.13M
SPRO icon
98
Spero Therapeutics
SPRO
$73M
$7.7M 0.3%
525,000
– –
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$7.67M 0.3%
49,000
– –
RARX
100
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.46M 0.29%
750,000
+150,000
+25% +$1.04M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Rock Springs Capital Management held 158 positions worth $2.6B, up 11% from $2.34B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q2 2018 filing shows 8 new, 60 increased, 24 reduced and 11 closed positions. Its largest new stake was West Pharmaceutical: 160,000 shares worth $15.9M. The largest sale was Bristol-Myers Squibb, an estimated $41.1M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Financials.

  • Rock Springs Capital Management's largest Q2 2018 buy was West Pharmaceutical: 160,000 shares worth $15.9M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q2 2018, an estimated $19.4M increase.
  • Rock Springs Capital Management's biggest Q2 2018 reduction was PRA Health Sciences, Inc., cutting an estimated $9.19M.
  • Rock Springs Capital Management fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $41.1M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $2.6B portfolio in Q2 2018.
  • Rock Springs Capital Management opened 8 new positions and closed 11 in Q2 2018.
  • Rock Springs Capital Management's portfolio value rose 11% quarter-over-quarter to $2.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.